Richmond biotech BrainBox Solutions Inc., the maker of an artificial intelligence-enabled concussion test, said Tuesday it has received a patent for one of the methods it uses to detect traumatic brain injuries.
The Brain Derived Neurotrophic Factor, as it is called, is just one component of the biomarker panel in the company’s testing for concussions. CEO Donna Edmonds said in a statement incorporating BDNF in its concussion panels helps the company generate an objective traumatic brain injury score that then can guide decision-making from health care providers.
The patent is based on the BrainBox’s discovery that a decrease in blood levels of BDNF alone are specific to the detection of concussions, the company said. The patent covers both the diagnosis of a traumatic brain injury and patient monitoring after an injury to help determine a return to work or the playing field.
The biotech said its intellectual property portfolio includes 17 patents protecting more than 30 proprietary…
Read the full story from the Washington Business Journal.
